NCT01126541View on ClinicalTrials.gov

SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Rheumatoid Arthritis
Interventions
DRUG

rituximab

Arm A: 1000 mg IV (one infusion) every 2 months \\nArm B: 2 x 1000 mg IV (2 infusions) every 2 months

Trial Locations (53)

4200

Saint-Etienne

11108

Narbonne

13013

Marseille

13616

Aix-en-Provence

14033

Caen

26000

Valence

29609

Brest

31054

Toulouse

31059

Toulouse

33505

Libourne

33600

Pessac

34295

Montpellier

35203

Rennes

38434

Échirolles

44035

Nantes

46005

Cahors

47923

Agen

51100

Reims

54511

Vandœuvre-lès-Nancy

56017

Vannes

59037

Lille

59322

Valenciennes

59462

Lomme

62600

Berck

62800

Liévin

63003

Clermont-Ferrand

64046

Pau

66046

Perpignan

67098

Strasbourg

69365

Lyon

69495

Pierre-Bénite

73106

Aix-les-Bains

75019

Paris

75475

Paris

75571

Paris

75651

Paris

75674

Paris

75679

Paris

75877

Paris

76233

Bois-Guillaume

76290

Montivilliers

80054

Amiens

80142

Abbeville

83100

Toulon

85925

La Roche-sur-Yon

86021

Poitiers

87042

Limoges

90016

Belfort

91106

Corbeil-Essonnes

92104

Boulogne-Billancourt

93009

Bobigny

94275

Le Kremlin-Bicêtre

06202

Nice

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01126541 - SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy | Biotech Hunter | Biotech Hunter